Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887090 | 0.94 | ALDH1A1 (0.60) | ALDH1A1HSD17B10LMNASOAT1TSHR | |
| Ethyl Acetate SCHEMBL10620330 | 0.80 | ALDH1A1 (0.82) | ALDH1A1HSD17B10LMNASOAT1TSHR | |
| SCHEMBL6314407 | 0.78 | ALDH1A1 (0.72) | ALDH1A1HSD17B10LMNASOAT1TSHR | |
| SCHEMBL11808669 | 0.78 | ALDH1A1 (0.60) | ALDH1A1HSD17B10LMNASOAT1TSHR | |
| SCHEMBL2161093 | 0.78 | — | — | |
| SCHEMBL2308025 | 0.76 | SOAT1 (0.70) | ALDH1A1HSD17B10LMNASOAT1TSHR | |
| Diethyl Pyrocarbonate SCHEMBL8342707 | 0.76 | SOAT1 (0.79) | ALDH1A1HSD17B10LMNASOAT1TSHR | |
| SCHEMBL8332085 | 0.76 | ALDH1A1 (0.57) | ALDH1A1HSD17B10LMNASOAT1TSHR | |
| SCHEMBL15413048 | 0.76 | ALDH1A1 (0.57) | ALDH1A1HSD17B10LMNASOAT1TSHR | |
| Hydrochloric Acid SCHEMBL28762476 | 0.76 | SOAT1 (0.70) | ALDH1A1HSD17B10LMNASOAT1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-12-07 | — | — | US | disclosed |
| CN-117042808-A | FAP activated serum half-life extending therapeutic conjugates | 阿瓦克塔生命科学有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4237012-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Avacta Life Sciences Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022094262-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-6613879-B1 | Of given formula; produrg which can be converted to a drug by fibroblast activation protein (FAP); cytotoxic; antiproliferative and anticarcinogenic agent | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-02 | — | — | US | disclosed |
| WO-2003064454-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-08-07 | — | — | WO | disclosed |
| EP-1333033-A1 | FAP-activated anti-tumor compounds | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-06 | — | — | EP | disclosed |
| US-20030055052-A1 | FAP-activated anti-tumor compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-20 | — | — | US | disclosed |
| US-20020155565-A1 | FAP-activated anti-tumor compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-24 | — | — | US | disclosed |
| WO-2002038591-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038590-A1 | FAP-ALPHA-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038187-A1 | FAP-ACTIVATED ANTI-TUMOUR PRODRUG | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-16 | — | — | WO | disclosed |
| EP-1180116-A2 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | Boehringer Ingelheim Pharma KG (DE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000071571-A2 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | ALDH1A1 317/4885HSD17B10 2761/4885LMNA 2108/4885 |
| US-20020155565-A1 | FAP-activated anti-tumor compounds | FAP, FIBP, DNPEP | ALDH1A1 1638/4885HSD17B10 2893/4885LMNA 1315/4885 |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | FAP, FIBP, FUCA2 | ALDH1A1 446/4885HSD17B10 3323/4885LMNA 966/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | ALDH1A1 749/4885HSD17B10 3557/4885LMNA 1857/4885 |
| US-20030055052-A1 | FAP-activated anti-tumor compounds | FAP, APC, FIBP | ALDH1A1 924/4885HSD17B10 2902/4885LMNA 1539/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | ALDH1A1 323/4885HSD17B10 2784/4885LMNA 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.